Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso

This study has been completed.
Holley-Cotec Pharmaceuticals Co., LTD.
Mahidol University
Information provided by (Responsible Party):
Sunil Parikh, University of California, San Francisco Identifier:
First received: February 17, 2009
Last updated: January 15, 2014
Last verified: January 2014
This will be an open-label trial in Burkina Faso assessing the pharmacokinetics of the antimalarial combination of dihydroartemisinin/piperaquine (DP, Duocotexcin) in children. Dihydroartemisinin-piperaquine is a promising candidate for first-line therapy of malaria. We hypothesize that the disposition and pharmacokinetics of DP will be altered in children, and this will alter the efficacy and/or toxicity of DP. We will test this hypothesis in this open-label trial in Burkina Faso. The target population includes residents, aged 6 months to 10 years in Bobo-Dioulasso. Children who present to the study clinics with symptoms suggestive of malaria will be screened with a thick blood smear. Subjects who meet selection criteria of treatment efficacy will be treated and followed up for 42 days. Pharmacokinetic sampling for DP will occur on selected follow-up days.

Condition Intervention Phase
Uncomplicated Malaria
Drug: Dihydroartemisinin-Piperaquine
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Study Start Date: August 2007
Study Completion Date: January 2009
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   6 Months to 10 Years   (Child)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Positive screening thick blood smear
  2. Fever (> 37.5ºC axillary) or history of fever in the previous 24 hours
  3. Age ≥ 6 months to 10 years
  4. Weight > 5 kg
  5. Absence of any history of serious side effects to study medications
  6. No evidence of a concomitant febrile illness in addition to malaria
  7. No history of antimalarial use in the previous two weeks
  8. P. falciparum mono-infection
  9. Parasite density 2000-200,000/ul
  10. Provision of informed consent and ability to participate in 42-day follow-up

Exclusion Criteria:

  1. Danger signs or evidence of severe malaria
  2. Hemoglobin levels < 5.0 gm/dL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00845533

Sponsors and Collaborators
University of California, San Francisco
Holley-Cotec Pharmaceuticals Co., LTD.
Mahidol University
Principal Investigator: Sunil Parikh, M.D., M.P.H. University of California, San Francisco
Principal Investigator: Philip J Rosenthal, M.D. University of California, San Francsico
Principal Investigator: Jean-Bosco Ouedraogo, M.D., PhD Institut de Receherche en Sciences de la Sante Bobo-Dioulasso
  More Information

Responsible Party: Sunil Parikh, Assistant Professor, University of California, San Francisco Identifier: NCT00845533     History of Changes
Other Study ID Numbers: H40380-31179-01
Study First Received: February 17, 2009
Last Updated: January 15, 2014

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents processed this record on April 24, 2017